Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.

In the post-rituximab era, patients with relapsed/refractory non-Hodgkin B-cell lymphoma (R/R B-NHL) responding to a platinum salt-based salvage regimen can potentially be cured after intensification followed by autologous stem cell transplantation, with the quality of the response to salvage predicting survival. The Bruton tyrosine kinase inhibitor ibrutinib, given as monotherapy or combined with other molecules, has proven effective in numerous B-cell lymphomas. To evaluate the safety of the combination of ibrutinib, rituximab, dexamethasone, and cytarabine with either cisplatin (R-DHAP) or oxaliplatin (R-DHAOx), we conducted a multicenter Phase 1b-II study in transplant-eligible R/R B-NHL patients, with ibrutinib given using a 3-by-3 dose-escalation design.

Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.

Background: Wound infections are the main cause of sepsis in patients with burns and increase burn-related morbidity and mortality. Bacteriophages, natural bacterial viruses, are being considered as an alternative therapy to treat infections caused by multidrug-resistant bacteria. We aimed to compare the efficacy and tolerability of a cocktail of lytic anti-Pseudomonas aeruginosa bacteriophages with standard of care for patients with burns.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained complete remission rate and a 78.9% survival over a 4.

[Diffuse large B cell lymphoma: management in 2012].

Diffuse Large B Cells Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and comprises a large number of different entities with different clinico-pathological characteristics. The role of positron emission tomography is essential during the initial staging and post treatment assessment, and potentially at early- or mid-treatment evaluation of response. First line therapy comprises immuno-chemotherapy with rituximab and different cytotoxic agents that differ for components, dosages and frequency of administration taking worldwide-recognized pre-treatment prognostic variables into account.

Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18-35 years old.

Background: Oral contraceptives (OCs) with estrogens and progestins may affect oxidative stress (OS) status.

Study Design: A group of 32 women using oral contraceptives (OCU) containing 0.03 mg ethinylestradiol and 3 mg drospirenone have been compared to a matched control group of 30 noncontraception users (NCU).

The Role of PET/CT in the Monitoring and Diagnosis of Pediatric Inflammatory Bowel Disease.

Ulcerative colitis and Crohn's disease are chronic immune-mediated inflammatory diseases that affect the digestive tract. Major progresses have been made in our comprehension the underlying molecular substrate of these diseases, and therapeutic algorithms have greatly changed over the past decade. In this article, we review the various methods for monitoring the activity of inflammatory bowel disease, with a particular emphasis on [F-18]2-fluoro-2-deoxyglucose PET and PET/CT imaging.

Complementary Assessment of Abdominopelvic Disorders with PET/CT and MRI.

This article reviews the current performance and status of PET/CT and MR imaging in four different abdominopelvic malignancies: cervical, pancreatic, and rectal cancers and liver metastases, as well as in Crohn's disease. The authors discuss the complementary aspects of these imaging techniques to evaluate the nature of the lesion, its local extent, and distant spread. These disease conditions represent pertinent clinical models in which PET/MRI may, if and when available, constitute a powerful tool in the management of patients.

Liver Metastases.

Many imaging techniques are available to evaluate metastatic spread to the liver. This article discusses the diagnostic performances of ultrasonography, computed tomography, magnetic resonance imaging, positron emission tomography and the dual modality PET/CT. Comparative data will be highlighted, and an attempt at defining new diagnostic algorithm will be made.

PET imaging for differentiating recurrent brain tumor from radiation necrosis.

The exact incidence of true radiation necrosis is largely unknown. It is probably much less frequent than indicated by MR or CT findings. Differentiating radiation necrosis from recurrent tumor is a diagnostic challenge, however, and has important implications for the patient's management.

PET imaging in assessing gastrointestinal tumors.

The clinical usefulness of FDG-PET imaging is now firmly established in various situations, such as the preoperative staging of esophageal cancer and recurrent colorectal carcinoma and the detection and staging of recurrent colorectal cancer when there is a clinical or biologic suspicion with inconclusive conventional findings. Encouraging results were obtained in the evaluation of the therapeutic response of various gastrointestinal malignancies, either during the treatment or after its completion. There is no firm consensus regarding its role in pancreatic cancer, either proved or suspected, but it may be valuable in selected clinical situations.